期刊
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
卷 36, 期 7, 页码 E448-E451出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPH.0000000000000005
关键词
everolimus; SEGA; tuberous sclerosis; spinal cord
资金
- Novartis
- NIH [R01CA172392]
- St. Baldrick's Foundation
- Alex's Lemonade Stand Foundation
- Childhood Brain Tumor Foundation
- CURE Childhood Cancer Foundation
- Children's Center for Neuroscience
Background: Brain subependymal giant cell astrocytomas (SEGAs) in patients with tuberous sclerosis have been reported to respond to everolimus. Methods: A 15-year-old male patient with intractable seizures and multiple SEGAs of the brain developed leptomeningeal enhancement and multiple metastatic, histologically confirmed SEGAs of the spinal cord. He received daily everolimus at a dose of 3 mg/m(2) for 6 weeks, which was then increased to 6 mg/m(2). Results: Magnetic resonance image of the brain and spine showed significant reduction in the size of SEGAs after 6 weeks of treatment. The patient has remained free of progression for 24 months. Additional benefits included: excellent seizure control, decrease in the size of cardiac rhabdomyomas, and improved quality of life. Conclusions: We describe a rare case of metastatic SEGA, which was successfully treated with everolimus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据